These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36738129)

  • 1. Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.
    Clephas PRD; Radhoe SP; Linssen GCM; Langerveld J; Plomp J; Smits JPP; Nagelsmit MJ; Rocca HB; Brugts JJ
    ESC Heart Fail; 2023 Apr; 10(2):1481-1487. PubMed ID: 36738129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
    Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
    JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists.
    Trevisan M; de Deco P; Xu H; Evans M; Lindholm B; Bellocco R; Barany P; Jernberg T; Lund LH; Carrero JJ
    Eur J Heart Fail; 2018 Aug; 20(8):1217-1226. PubMed ID: 29667759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure.
    Henrysson J; Thunström E; Chen X; Fu M; Basic C
    ESC Heart Fail; 2023 Feb; 10(1):66-79. PubMed ID: 36161782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
    Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
    Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
    Brunner-La Rocca HP; Linssen GC; Smeele FJ; van Drimmelen AA; Schaafsma HJ; Westendorp PH; Rademaker PC; van de Kamp HJ; Hoes AW; Brugts JJ;
    JACC Heart Fail; 2019 Jan; 7(1):13-21. PubMed ID: 30606482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction.
    Rossignol P; Duarte K; Girerd N; Karoui M; McMurray JJV; Swedberg K; van Veldhuisen DJ; Pocock S; Dickstein K; Zannad F; Pitt B
    Eur J Heart Fail; 2020 Aug; 22(8):1402-1411. PubMed ID: 31919958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyskalemia in people at increased risk for heart failure: findings from the heart 'OMics' in AGEing (HOMAGE) trial.
    Monzo L; Ferreira JP; Cleland JGF; Pellicori P; Mariottoni B; Verdonschot JAJ; Hazebroek MR; Collier TJ; Cuthbert JJ; Pieske B; Edelmann F; Petutschnigg J; Khan J; Ahmed FZ; Girerd N; Bozec E; Díez J; González A; Clark AL; Cosmi F; Staessen JA; Heymans S; Rossignol P; Zannad F
    ESC Heart Fail; 2022 Dec; 9(6):4352-4357. PubMed ID: 36065795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry.
    Savarese G; Carrero JJ; Pitt B; Anker SD; Rosano GMC; Dahlström U; Lund LH
    Eur J Heart Fail; 2018 Sep; 20(9):1326-1334. PubMed ID: 29578280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure.
    Maggioni AP; Dondi L; Andreotti F; Calabria S; Iacoviello M; Gorini M; Gonzini L; Piccinni C; Ronconi G; Martini N
    Eur J Clin Invest; 2021 Aug; 51(8):e13551. PubMed ID: 33786826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
    Butler J; Anker SD; Lund LH; Coats AJS; Filippatos G; Siddiqi TJ; Friede T; Fabien V; Kosiborod M; Metra M; Piña IL; Pinto F; Rossignol P; van der Meer P; Bahit C; Belohlavek J; Böhm M; Brugts JJ; Cleland JGF; Ezekowitz J; Bayes-Genis A; Gotsman I; Goudev A; Khintibidze I; Lindenfeld J; Mentz RJ; Merkely B; Montes EC; Mullens W; Nicolau JC; Parkhomenko A; Ponikowski P; Seferovic PM; Senni M; Shlyakhto E; Cohen-Solal A; Szecsödy P; Jensen K; Dorigotti F; Weir MR; Pitt B
    Eur Heart J; 2022 Nov; 43(41):4362-4373. PubMed ID: 35900838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.
    Allen LA; Shetterly SM; Peterson PN; Gurwitz JH; Smith DH; Brand DW; Fairclough DL; Rumsfeld JS; Masoudi FA; Magid DJ
    Circ Heart Fail; 2014 Jan; 7(1):43-50. PubMed ID: 24281136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
    Ferreira JP; Zannad F; Butler J; Filipattos G; Ritter I; Schüler E; Kraus BJ; Pocock SJ; Anker SD; Packer M
    Eur Heart J; 2022 Aug; 43(31):2984-2993. PubMed ID: 35687107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facility variation and predictors of serum potassium monitoring after initiation of a mineralocorticoid receptor antagonist in patients with heart failure.
    Chauhan V; Dev S; Pham M; Lin S; Heidenreich P
    Am Heart J; 2015 Sep; 170(3):543-9. PubMed ID: 26385038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.